Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda’s Millennium division announces Sunesis collaboration

Takeda’s Millennium division announces Sunesis collaboration

8th April 2011

Takeda's oncology-focused subsidiary Millennium is to enter into collaboration with Sunesis Pharmaceuticals on the development of new cancer treatments.

The partnership will see the two companies jointly developing an oral, selective pan-Raf kinase inhibitor owned by Sunesis, as well as one additional oncology-related kinase inhibitor programme.

Both of these compounds were created as part of a collaboration between Sunesis and Biogen Idec, but Millennium has purchased rights to the assets following Biogen Idec's decision to focus on neurology.

The deal also sees Millennium pay a $4 million (2.44 million pounds) upfront fee to Sunesis, with further milestone payments and royalties going up to a potential $60 million.

Dr Nancy Simonian, chief medical officer at Millennium, said: "These kinase inhibitor programmes represent an important addition to our portfolio and reflect our strategy to develop novel oncology therapies by targeting the underlying pathways of the disease process."

Last month, Takeda signed an agreement with Intra-Cellular Therapies to develop new treatments for schizophrenia and other neurological conditions.ADNFCR-8000103-ID-800492433-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.